Aether Industries is a specialty chemicals company that behaves more like a contract research house with its own factories - it was founded in 2013 in Surat, Gujarat, by the Desai family, who together bring over 125 years of chemical industry experience, and spent its first four years building R&D capabilities before selling a single product. The recurring approach is to master a matrix of eight chemistry and eight technology competencies in-house, then deploy that breadth across three mutually reinforcing business models - proprietary manufacturing, contract research, and exclusive manufacturing - so that a molecule developed for a client’s R&D team can become a long-term exclusive supply contract and eventually a product the company owns and sells globally. # Business segments Three engines that feed each other - proprietary products built from in-house R&D, innovation services that embed the company inside global R&D organisations, and exclusive multi-year manufacturing partnerships with industry giants - all resting on a single R&D and pilot-plant backbone. ## 1. Large Scale Manufacturing: proprietary products, owned and sold globally **Aether picks molecules that no one else makes in India, develops the process entirely in-house, and becomes the world’s largest or second-largest manufacturer - every one of its 29-plus products is a 100% import substitute.** - **First-to-India selection** - the company only pursues molecules requiring at least a four-step synthetic sequence that have no active manufacturer in India, so it enters as the domestic pioneer and builds from there. - **Global market-share positions** - it was the largest manufacturer in the world by volume for 4MEP (28% share, used in blood-pressure drugs), T2E (nearly 50% share, for blood thinners), NODG (46% share, for pain relievers), and HEEP (34% share, for antipsychotics), and the second-largest for MMBC and DVL, making it the sole Indian producer in each case. - **High-value niche pricing** - the average selling price across the portfolio was around ₹1,300-1,800 per kg, reflecting molecules that sit close to the final drug or formulation rather than at the commodity end of the value chain. - **The “golden transition” feeder** - molecules that start as contract research projects for global innovators can graduate into regular commercial supplies and join the contract/exclusive manufacturing portfolio, so the proprietary pipeline is constantly replenished by the other two business models. ## 2. Contract Research and Manufacturing Services: the innovation shop for global R&D teams **Aether embeds its scientists and engineers inside the discovery pipelines of pharma and agrochemical innovators, reconstructing their lab-scale molecules into economical, scalable manufacturing processes - and it runs one of the largest pilot plants in the world to prove them.** - **R&D-as-a-service** - the model spans paper research, lab process development at gram scale, pilot scale-up at kilogram scale, and clinical-trial quantities at hundreds of kilograms, all the way to commercial readiness, making Aether a one-stop shop for outsourced innovation. - **The pilot plant is the proving ground** - with over 100 reactors handling both batch and continuous technologies, the facility can run more than 15 projects simultaneously and generates the scale-up data that makes the first factory run routine. - **Relationships at the technical top** - CRAMS engagements connect Aether with CTOs, technical directors, and VPs of R&D at customer organisations, creating the relationships that later convert into exclusive manufacturing contracts. - **Engineering from day one** - chemists and chemical engineers work together from the inception of every project, so process innovation is built into the molecule’s manufacturing route rather than retrofitted after the chemistry is fixed. ## 3. Contract / Exclusive Manufacturing: multi-year dedicated supply for industry giants **Aether locks in long-term, often take-or-pay contracts where it builds dedicated production lines for a single customer’s product - the customer gets guaranteed supply, and Aether gets predictable revenue with raw-material costs passed through.** - **Marquee partnerships with dedicated sites** - Baker Hughes has a five-year agreement for six oilfield pour-point depressants made at the dedicated Site 4; Saudi Aramco’s CO₂-based polyols run on a 2,000-tonne-per-year line; Milliken signed a ten-year deal with Site 3+ fully dedicated to one strategic product. - **Take-or-pay and formula-based pricing** - contracts typically run three to five years with pricing mechanisms that pass raw-material cost fluctuations to the customer, so Aether’s margin is protected from input-price swings. - **The CRAMS-to-CEM pipeline** - the Milliken partnership began as a CRAMS engagement and transitioned into exclusive manufacturing, illustrating the “golden transition” that turns innovation services into locked-in production revenue. - **Structural stickiness** - because entire production blocks are purpose-built for a single customer’s molecule, switching costs are high for the customer and revenue visibility is high for Aether. # R&D and pilot plant: the shared engine underneath all three businesses **Every product the company has ever sold was developed, scaled, and engineered entirely by its in-house R&D team - 286 scientists and engineers working across a pilot plant described as one of the largest in the world, with a new R&D building underway that will double capacity.** - **Chemistry-plus-technology breadth** - the company built eight distinct chemistry competencies and eight technology competencies from scratch, so it is not dependent on any single reaction type or end-market. - **Scale-up without surprises** - the internal mantra is that “the first manufacturing should be had with a cup of tea,” meaning the process is so thoroughly validated in the pilot plant that the initial production run is routine. - **Tripling and doubling** - the R&D facility was expanded in FY23 from 17 to 55 fume hoods enabling over 110 experiments per day, and a completely new R&D building with roughly 140 fume hoods across 15 labs is expected in FY28. - **Leadership from global industry** - the Chief Technology Officer spent over 30 years at Dow Chemical in process-chemistry and engineering-science leadership roles and holds 22 US patents, anchoring the R&D function with deep industrial experience. # Group structure and partners **Aether is the listed parent with one wholly owned subsidiary that runs the Baker Hughes dedicated site, and its growth is built on deep bilateral partnerships with global innovators rather than joint ventures or equity stakes.** - **Aether Speciality Chemicals Limited** - the wholly owned subsidiary operates Site 4, commissioned in March 2024 and dedicated to the Baker Hughes contract, with the subsidiary structure providing a 7% income-tax benefit. - **Partnership model** - key relationships include Saudi Aramco (CO₂-based polyols), Baker Hughes (oilfield chemicals), SEQENS (bio-based products), Milliken (a ten-year manufacturing mandate), Polaroid (exclusive R&D and supply for instant-photography chemistry), and Otsuka Chemical (a ten-year exclusive supply agreement for two intermediates), all structured as long-term commercial contracts rather than equity alliances. - **Adjacent bets** - the company has a strategic agreement with a major lithium-ion battery producer for electrolyte additives and a plastic-upcycling collaboration with Novoloop, extending its chemistry platform into electronic chemicals and circular materials.